Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.

Hiroshi NakaseS MotoyaT MatsumotoK WatanabeT HisamatsuN YoshimuraT IshidaS KatoT NakagawaMotohiro EsakiM NagahoriT MatsuiY NaitoT KanaiY SuzukiM NojimaM WatanabeT Hibinull null

Published in: Alimentary pharmacology & therapeutics (2017)

Adalimumab trough levels and AAA occurrence were significantly associated with clinical remission. Higher 6TGN affected AAA negativity. The combination therapy is beneficial in some relevant aspects for CD patients. (UMIN Registration No. 000005146).

Keyphrases

combination therapy
rheumatoid arthritis
end stage renal disease
newly diagnosed
ulcerative colitis
juvenile idiopathic arthritis
risk assessment
clinical trial
study protocol
prognostic factors
disease activity
emergency department
phase ii
phase iii
hidradenitis suppurativa
open label
adverse drug
double blind